Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 1,377

Document Document Title
WO/2015/062556A1
Use of a composition comprising plant based saponins for regulating and balancing gut microflora in a subject.  
WO/2014/189351A3
The present invention describes a process to obtain the compound 6-0-palmitoyl-3-beta-D-glucopyranosyl-campesterol (6-O-PGC) from Lopezia racemosa extracts. The procedure to prepare extracts and fractions from Lopezia racemosa wild plant...  
WO/2014/146089A3
Novel mogrosides and methods for heir purification are provided herein. In addition, compositions comprising said novel mogrosides and methods for preparing the same are provided. The present invention relates generally to novel mogrosid...  
WO/2014/194068A1
Compounds which are glycosylates of an A-ring of a cardiotonic steroid, wherein the steroid is attached to the anomeric position of (a) a monosaccharide comprising a C-4 amino group, or (b) an oligosaccharide are provided.  
WO/2014/189351A2
The invention relates to the method for producing the compound 6-0-palmitoyl-3-0-β-P-D-glucopyranosyl-campesterol(6-O-PGC) with a novel structure and with in vivo anti-inflammatory activity, from plant extracts obtained from in vitro c...  
WO/2014/150127A1
Fruit extracts containing mogrol glycosides substituted with five or more sugar residues per molecule such as mogroside V may be treated with acid or enzymes to increase the content of mogrol glycosides such as siamenoside I and mogrosid...  
WO/2014/146089A2
Novel mogrosides and methods for heir purification are provided herein. In addition, compositions comprising said novel mogrosides and methods for preparing the same are provided.  
WO/2013/149570A1
Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal ...  
WO/2013/149571A1
Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.  
WO/2013/143494A1
Disclosed is a protopanaxatriol ginsenoside preparation method, comprising the following steps: (a) protecting the hydroxyl of the protopanaxatriol, exposing a 20-position hydroxyl and at least one of 3-position, 6-position and 12-positi...  
WO/2013/100712A1
The present invention relates to a novel blocker for vascular leakage. The novel blocker for vascular leakage of the present invention inhibits the apoptosis of endothelial cells, suppresses the formation of actin stress fibers induced b...  
WO/2013/040441A1
The invention relates to a drug conjugate including a drug and a plant steroid. The drug conjugate may target the drug for intestinal cell delivery, and thus may be used to treat diseases, including intestinal diseases, or to affect inte...  
WO/2012/127176A1
The present invention relates to novel neurosteroids, especially derivatives of allopregnanolone and of epiallopregnanolone of formula (I) and the uses thereof as medicament for the treatment of neuropathologies, in particular neuropathi...  
WO/2012/100018A1
Stabilized benzyl phosphonic acid and naphthyl phosphonic acid analog compounds are effective in inhibiting the activity of autotaxin.  
WO/2012/079275A1
Provided is a method for preparing fluticasone furoate (fluoromethyl 6α,9α-difluoro-11β-hydroxy-16a-methyl-17α-[(2-furoyl)oxy ]-3-one androsta-1,4-diene-17β-thiocarboxylate) represented by Formula I. The method comprises: 1) forming...  
WO/2012/068832A1
Provided is a method for preparing mogroside IV, which comprises hydrolyzing mogroside V, Momordica grosvenori fruits, or extracts of Momordica grosvenori fruits containing mogroside V with β-glucosidase. The content of mogroside IV in ...  
WO/2012/027957A1
Bufalin derivatives of formula I and the pharmaceutical compositions thereof are provided, wherein the radicals have the meanings as defined in the invention. The use of these derivatives is also provided.  
WO/2011/077800A1
A neutral fat level control agent, a cholesterol level control agent, a free fatty acid level control agent and an anti-obesity agent, each characterized by comprising at least one of protopanaxatriol, panaxatriol, protopanaxadiol and pa...  
WO/2011/073419A1
The present invention relates to a compound of formula (I) for its use for reversing or inhibiting multidrug resistance.  
WO/2011/036557A1
Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that b...  
WO/2011/010364A1
Disclosed is a novel compound having a neurite-outgrowing activity and is therefore useful for the prevention or treatment of neurodegenerative diseases. Specifically disclosed is a compound represented by formula (I) [wherein X represen...  
WO/2011/002033A1
A glucose metabolism-improving agent having an activity of suppressing the increase in an after-meal glucose level, an activity of decreasing a fasting glucose level, an activity of regulating a glucose metabolism-related measure in seru...  
WO/2010/088866A3
This invention relates to novel saponin compounds of formula II wherein MBz denotes p-methoxybenzoyl, and R is selected from the group comprising C6-10 aryl, C6-10 aryl-C1-4 alkyl-, C1-18 alkanoyl, C3-18 alkenoyl, C6-10 aryl-C(O)-, C6-10...  
WO/2010/048710A8
The invention relates to compositions for use in animal models of neurodegenerative disease and methods therefor. More particularly, the invention relates to the use of neurotoxic sterol glycosides or neurotoxic glycolipids, or combinati...  
WO/2010/102952A1
The present invention relates to a process of reducing the content of steryl glycoside in a bio-diesel composition which comprises a step of contacting the composition with an enzyme being capable of acylating the steryl glycoside.  
WO/2010/095741A1
Disclosed is a novel steroid derivative which is expected to exhibit an NGF activity. Specifically disclosed is a compound represented by formula (A) or (B). (In the formulae (A) and (B), n represents 1 or 2.)  
WO/2010/058794A1
Disclosed is a highly safe antioxidant which suppress oxidation of biological components, particularly oxidation of lipids, and can be used as a pharmaceutical product, food, drink, food additive, external preparation for the skin and th...  
WO/2010/048710A1
The invention relates to compositions for use in animal models of neurodegenerative disease and methods therefor. More particularly, the invention relates to the use of neurotoxic sterol glycosides or neurotoxic glycolipids, or combinati...  
WO/2010/004423A3
The present invention relates to a method for reducing the amount of steryl glycoside in an oil or fat (e.g. a biofuel substrate) and/or a biofuel, the method comprising admixing one or more enzymes with an oil or fat comprising steryl g...  
WO/2010/041681A1
Provided is a novel compound which is a sominone derivative represented by formula (1) or a salt thereof and which is useful as an agent for the prevention and treatment of neurological disease.  
WO/2010/029915A1
Disclosed is a simple method for producing a plant containing sapogenin, which contains a large quantity of sapogenin and has outstanding taste and safety, using a plant containing saponin as the raw material. The method for producing a ...  
WO/2010/027992A1
A method of preventing preeclampsia including administering to a patient during an early stage of pregnancy a prophylactically-effective amount of resibufogenin. The administration of resibufogenin is periodically repeated. The method se...  
WO/2009/106360A3
The present invention relates to a method for purifying biodiesel, biodiesel precursors, or the mixtures thereof, which contain at least one glycoside, wherein biodiesel or a biodiesel precursor or a mixture thereof is incubated with at ...  
WO/2009/135449A1
The invention relates to novel ligands of the estrogen receptors α and β of general formula (II), which are useful as active substance of pharmaceuticals, for example pharmaceutical compositions useful for hormone replacement therapy, ...  
WO/2009/106360A2
The present invention relates to a method for purifying biodiesel, biodiesel precursors, or the mixtures thereof, which contain at least one glycoside, wherein biodiesel or a biodiesel precursor or a mixture thereof is incubated with at ...  
WO/2009/024103A3
The present invention relates to natural brassinosteroids of general formula (I), wherein R is CH2 or O-CH2 group, R2 is hydrogen or hydroxyl, R3 is hydroxyl, R24 is alkyl or alkenyl, which are selected from the group consisting of methy...  
WO/2009/023975A3
Provided is the novel sweetener and sweetness enhancer iso-mogroside V, compositions comprising the sweetener/sweetness enhancer for use in consumables (food products and products place in the oral cavity including mouth wash and other d...  
WO/2009/024103A2
The present invention relates to natural brassinosteroids of general formula (I), wherein R is CH2 or O-CH2 group, R2 is hydrogen or hydroxyl, R3 is hydroxyl, R24 is alkyl or alkenyl, which are selected from the group consisting of methy...  
WO/2009/023975A2
Provided is the novel sweetener and sweetness enhancer iso-mogroside V, compositions comprising the sweetener/sweetness enhancer for use in consumables (food products and products place in the oral cavity including mouth wash and other d...  
WO/2008/137599A3
Novel 2-alkoxyestradiol analogs, pharmaceutical compositions and methods of treatment of proliferative and angiogenesis associated conditions are disclosed.  
WO/2008/127381A3
This disclosure provides improved derivatives of artemisinin; pharamaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventi...  
WO/2008/136199A1
A process for producing a compound represented by the following formula (2): (2) (wherein R1 means hydrogen, methyl, or CH2OH; R2 means hydrogen or methyl; R3 means hydrogen or hydroxy; R4 means hydrogen or hydroxy; and R5 means hydroxy,...  
WO/2008/127381A2
This disclosure provides improved derivatives of artemisinin; pharamaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventi...  
WO/2008/109936A1
The present invention provides a compound of Formula I, pharmaceutical compositions and methods of use thereof.  
WO/2008/102716A1
Disclosed is an agent for treatment of ADHD-related diseases, which contains a compound represented by the formula (1) below or at least one pharmaceutically acceptable salt thereof as an active ingredient. (1) (In the formula, R1 and R2...  
WO/2008/078362A1
An antitumor agent containing at least one compound selected from the group consisting of nerigoside, oleandrigenin, sarmentoside, oleaside A, oleandrin, 8β-hydroxy odoroside A, narciclasine, trans-dihydronarciclasine and bisdeoxynarcic...  
WO/2007/039346A3
A photoresist composition including a polymer, a photoacid generator and a dissolution modification agent, a method of forming an image using the photoresist composition and the dissolution modification agent composition. The dissolution...  
WO/2008/047149A1
A stable aqueous pharmaceutical composition comprising anhydrous mometasone furoate and a pharmaceutically acceptable carrier.  
WO/2007/076163A3
The present disclosure concerns a process for removing steryl glycosides or monoacylglycerols from biodiesel by contact of the biodiesel with an absorbant, or filter aid. Treated biodiesel as well as steryl glycosides derived from biodie...  
WO/2008/028584A1
The invention relates to preparations for oral administration, containing (a) physiologically active fatty acids with 16 to 26 carbon atoms and 2 to 6 double bonds, the esters or glycerides thereof and (b) Hoodia extracts or the steroid ...  

Matches 51 - 100 out of 1,377